HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Yu, L. Articles by Ferrara, N. Search for Related Content PubMed PubMed Citation Articles by Yu, L. Articles by Ferrara, N.

Interaction between Bevacizumab and Murine VEGF-A: A Reassessment

From Genentech, Inc., South San Francisco, California.

PURPOSE. Bevacizumab is a humanized anti-human VEGF-A monoclonal antibody (mAb) approved by the United States Food and Drug Administration for cancer therapy and used off label to treat neovascular age-related macular degeneration. Earlier studies characterized bevacizumab as species specific and lacking the ability to neutralize murine (m) VEGF-A. However, a recent study reported that bevacizumab is a potent inhibitor of hemangiogenesis and lymphangiogenesis in murine models. The authors sought to reassess the interaction between bevacizumab and mVEGF-A.

METHODS. The authors performed Western blot analysis, plasmon resonance by BIAcore, and endothelial cell proliferation assays to characterize the interaction between bevacizumab and mVEGF-A. They also tested whether bevacizumab had any effects in two in vivo murine models, laser-induced choroidal neovascularization (CNV) and melanoma growth.

RESULTS. Western blot detected a very weak interaction, but BIAcore detected no measurable interaction between mVEGF and bevacizumab. Bevacizumab failed to inhibit mVEGF-stimulated endothelial cell proliferation. In addition, bevacizumab was indistinguishable from the control antibody in the CNV and tumor models, whereas a cross-reactive anti–VEGF-A mAb had dramatic inhibitory effects.

CONCLUSIONS. Bevacizumab has an extremely weak interaction with mVEGF-A, which fails to result in immunoneutralization as assessed by several bioassays.

This article has been cited by other articles:

				C. Q. Yu, M. Zhang, K. I. Matis, C. Kim, and M. I. Rosenblatt Vascular Endothelial Growth Factor Mediates Corneal Nerve Repair Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 3870 - 3878. [Abstract] [Full Text] [PDF]

				C. Campa, I. Kasman, W. Ye, W. P. Lee, G. Fuh, and N. Ferrara Effects of an Anti-VEGF-A Monoclonal Antibody on Laser-Induced Choroidal Neovascularization in Mice: Optimizing Methods to Quantify Vascular Changes Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 1178 - 1183. [Abstract] [Full Text] [PDF]

eLetters: